Heart-rate-lowering drug ivabradine reduces death when added to treatments in heart failure patients

Aug 29, 2010

The heart-rate-lowering drug ivabradine significantly reduces the risk of cardiovascular death and hospitalisation for worsening heart failure when added to standard treatment in patients with heart failure and a high heart rate, according to the first of two Articles published Online First in The Lancet, and being presented at the European Society of Cardiology Annual Congress in Stockholm. A second Article concludes that a high heart rate is an independent risk factor for heart failure and that lowering of heart rates is an important treatment target for patients with heart failure.

The Systolic Heart Failure treatment with the If inhibitor ivabradine Trial (SHIFT) investigated whether lowering heart rate with ivabradine reduces cardiovascular death and admission to hospital with worsening heart failure among patients with , systolic dysfunction, and a high heart rate (70 beats per minute [bpm] or higher), over a median of 22.9 months' follow-up. 6505 patients from 37 countries were randomly assigned to ivabradine (starting dose 5 mg adjusted to a maximum of 7.5 mg twice daily; 3241) or placebo (3264) in addition to standard heart failure treatments.

Overall, treatment with ivabradine significantly reduced the risk of major heart failure outcomes by 18% compared to placebo. 16% of patients taking ivabradine were admitted to hospital with worsening heart failure compared to 21% in the placebo group, and 3% of patients in the ivabradine group died due to heart failure compared to 5% in the placebo group. Additionally, treatment with ivabradine was associated with an average reduction in heart rate of 15 bpm.

Ivabradine was safe and generally well tolerated with serious side effects occurring more frequently in the placebo group (3847 events) than in the ivabradine group (3388 events).

They conclude: "Our results support the importance of heart-rate reduction with ivabradine for improvement of clinical outcomes in heart failure and confirm that heart-rate modulation can interfere with progression of disease."

To further evaluate these findings, Michael Böhm from the Universitätsklinikum des Saarlandes in Germany, together with the SHIFT authors, examined whether raised resting heart rate at the start of the study was a risk factor for subsequent cardiovascular events. Analysing data from the SHIFT study, they calculated the likelihood of cardiovascular death and hospitalisation for worsening heart failure in patients with highest (≥87 bpm) and the lowest (70-72 bpm) pretreatment heart rates, and after 28 days of treatment with ivabradine.

Overall, placebo-treated patients with the highest heart rates were more than twice as likely to die or experience a cardiovascular event. For every increase of 5 bpm from the start of the study, there was a 16% increased risk of cardiovascular death or .

Additionally, there was a direct association between heart rate at 28 days after treatment with ivabradine and cardiac outcomes. Patients with heart rates lower than 60 bpm at 28 days had fewer events (17.4%) during the study compared to patients with heart rates of 75 bpm or higher (32.4%).

The authors say: "There is a continuous direct association between baseline heart rate and outcomes. The risk is modified and significantly decreased by ivabradine. The effect of ivabradine on heart rate is most pronounced in patients with high baseline values and correspondingly high reductions in heart rate due to ivabradine treatment."

They conclude: "The lowest heart rates achieved on treatment are associated with the best outcomes, and because the incremental benefit of ivabradine was obtained by titration of the drug to heart rates lower than 60 bpm, we estimate that this target, when tolerated, should be pursued by patients with chronic heart failure."

In a Comment, John Teerlink from the University of California, San Francisco, USA, says: "Ivabradine therapy might reduce heart-failure hospitalisations when added to contemporary heart-failure therapies. However, whether ivabradine can improve outcomes in addition to optimally managed heart failure therapies or its benefits relative to other therapies, especially beta blockers, remains unknown. The results from SHIFT provide the basis for additional trials to test these important and clinically relevant questions... Until these questions are answered, the place of ivabradine in therapies remains unclear."

Explore further: Feds vows to publicize vaccine injury help program

More information: www.thelancet.com/journals/lan… (10)61198-1/abstract

add to favorites email to friend print save as pdf

Related Stories

Heart failure treated 'in the brain'

Mar 25, 2008

Beta-blockers heal the heart via the brain when administered during heart failure, according to a new study by UCL (University College London). Up to now, it was thought that beta-blockers work directly on the heart, but ...

New heart failure device is tested

Oct 17, 2006

Physicians at 50 U.S. medical facilities are taking part in a multinational clinical trial of a device designed to help heart failure victims.

Recommended for you

US approves new, hard-to-abuse hydrocodone pill (Update)

Nov 20, 2014

U.S. government health regulators on Thursday approved the first hard-to-abuse version of the painkiller hydrocodone, offering an alternative to a similar medication that has been widely criticized for lacking ...

Soaring generic drug prices draw Senate scrutiny

Nov 20, 2014

Some low-cost generic drugs that have helped restrain health care costs for decades are seeing unexpected price spikes of up to 8,000 percent, prompting a backlash from patients, pharmacists and now Washington ...

Only half of patients take their medications as prescribed

Nov 20, 2014

The cost of patients not taking their medications as prescribed can be substantial in terms of their health. Although a large amount of research evidence has tried to address this problem, there are no well-established ...

User comments : 4

Adjust slider to filter visible comments by rank

Display comments: newest first

CarolinaScotsman
not rated yet Aug 29, 2010
Other standard treatments for heart patients, such as beta blockers, already lower heart rates substantialy.
Hurt
not rated yet Sep 03, 2010
in fact the title of the article is deceptive; the drug reduced a composite endpoint of cardiovalscular death and hospitalisation, however the reduction was mainly due to hospitalisations, while the cardiovascular death outcome didnt change.
Jackdean
not rated yet Sep 22, 2010
That's really a great news on the drug Ivabradine. I have been taking this for while fully happy to see ful info about this drug. This drug comes in 5mg and 7.5mg dosages. I take 5 mg dosage, it is easily available online.I buy from International Drug Mart.
cindrella_jack
not rated yet Oct 07, 2010
Yes Ivabradine has been proved to prevent heart attacks in clinical trials. It is available in 5mg and 7.5mg dosages. http://blog.inter...failure/

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.